OBJECTIVES: We evaluated the efficacy of a peer-mentoring behavioral intervention designed to reduce risky distributive injection practices (e.g., syringe lending, unsafe drug preparation) among injection drug users with hepatitis C virus (HCV) infection. METHODS: A randomized trial with a time-equivalent attention-control group was conducted among 418 HCV-positive injection drug users aged 18 to 35 years in 3 US cities. Participants reported their injection-related behaviors at baseline and at 3- and 6-month follow-ups. RESULTS: Compared with the control group, intervention-group participants were less likely to report distributive risk behaviors at 3 months (odds ratio [OR]=0.46; 95% confidence interval [CI]=0.27, 0.79) and 6 months (OR=0.51; 95% CI=0.31, 0.83), a 26% relative risk reduction, but were no more likely to cite their HCV-positive status as a reason for refraining from syringe lending. Effects were strongest among intervention-group participants who had known their HCV-positive status for at least 6 months. Peer mentoring and self-efficacy were significantly increased among intervention-group participants, and intervention effects were mediated through improved self-efficacy. CONCLUSIONS: This behavioral intervention reduced unsafe injection practices that may propagate HCV among injection drug users.
RCT Entities:
OBJECTIVES: We evaluated the efficacy of a peer-mentoring behavioral intervention designed to reduce risky distributive injection practices (e.g., syringe lending, unsafe drug preparation) among injection drug users with hepatitis C virus (HCV) infection. METHODS: A randomized trial with a time-equivalent attention-control group was conducted among 418 HCV-positive injection drug users aged 18 to 35 years in 3 US cities. Participants reported their injection-related behaviors at baseline and at 3- and 6-month follow-ups. RESULTS: Compared with the control group, intervention-group participants were less likely to report distributive risk behaviors at 3 months (odds ratio [OR]=0.46; 95% confidence interval [CI]=0.27, 0.79) and 6 months (OR=0.51; 95% CI=0.31, 0.83), a 26% relative risk reduction, but were no more likely to cite their HCV-positive status as a reason for refraining from syringe lending. Effects were strongest among intervention-group participants who had known their HCV-positive status for at least 6 months. Peer mentoring and self-efficacy were significantly increased among intervention-group participants, and intervention effects were mediated through improved self-efficacy. CONCLUSIONS: This behavioral intervention reduced unsafe injection practices that may propagate HCV among injection drug users.
Authors: David W Purcell; Lisa R Metsch; Mary Latka; Scott Santibanez; Cynthia A Gómez; Lois Eldred; Carl A Latkin Journal: J Acquir Immune Defic Syndr Date: 2004-10-01 Impact factor: 3.731
Authors: Lorna E Thorpe; Lawrence J Ouellet; Ronald Hershow; Susan L Bailey; Ian T Williams; John Williamson; Edgar R Monterroso; Richard S Garfein Journal: Am J Epidemiol Date: 2002-04-01 Impact factor: 4.897
Authors: D S Metzger; B Koblin; C Turner; H Navaline; F Valenti; S Holte; M Gross; A Sheon; H Miller; P Cooley; G R Seage Journal: Am J Epidemiol Date: 2000-07-15 Impact factor: 4.897
Authors: Don C Des Jarlais; Theresa Perlis; Kamyar Arasteh; Holly Hagan; Judith Milliken; Naomi Braine; Stanley Yancovitz; Donna Mildvan; David C Perlman; Carey Maslow; Samuel R Friedman Journal: J Acquir Immune Defic Syndr Date: 2004-02-01 Impact factor: 3.731
Authors: Lisa R Metsch; Margaret Pereyra; David W Purcell; Carl A Latkin; Robert Malow; Cynthia A Gómez; Mary H Latka Journal: J Acquir Immune Defic Syndr Date: 2007-11-01 Impact factor: 3.731
Authors: April M Young; Richard A Crosby; Carrie B Oser; Carl G Leukefeld; Dustin B Stephens; Jennifer R Havens Journal: J Med Virol Date: 2012-09 Impact factor: 2.327
Authors: Eileen V Pitpitan; Thomas L Patterson; Daniela Abramovitz; Alicia Vera; Gustavo Martinez; Hugo Staines; Steffanie A Strathdee Journal: Health Psychol Date: 2015-06-29 Impact factor: 4.267
Authors: Lydia N Drumright; Holly Hagan; David L Thomas; Mary H Latka; Elizabeth T Golub; Richard S Garfein; John D Clapp; Jennifer V Campbell; Sebastian Bonner; Farzana Kapadia; Thelma King Thiel; Steffanie A Strathdee Journal: J Hepatol Date: 2010-11-24 Impact factor: 25.083
Authors: Carol Strike; Daniel Z Buchman; Russell C Callaghan; Cass Wender; Susan Anstice; Brian Lester; Nick Scrivo; Janine Luce; Margaret Millson Journal: Harm Reduct J Date: 2010-02-09